Morton Grove Pharmaceuticals signs agreement with Cipla India
Morton Grove Pharmaceuticals (MGP), of Illinois, has signed a long-term exclusive agreement with Cipla, a major Indian pharmaceutical company based in Mumbai.
Morton Grove Pharmaceuticals (MGP), of Illinois, has signed a long-term exclusive agreement with Cipla, a major Indian pharmaceutical company based in Mumbai.
Cipla will develop, manufacture, package and supply certain prescription pharmaceutical oral liquid and semi-solid products for MGP to market and sell in the US.
Cipla will also provide formulation and analytical development activities in support of MGP's new product development programme. All regulatory applications will be filed and owned by MGP. Cipla began work on the selected products in 2003, and MGP plans to file a number of regulatory applications in late 2004.
'This agreement marks a major milestone in the development of MGP's business and product offering for the long term. It is the first collaborative agreement we have entered into,' said Brian Tambi, MGP's president and ceo. 'In addition to providing new product opportunities, Cipla's support will significantly broaden and strengthen the content of our new product development programme and measurably reduce timelines to new product launches.'